2023-04-26 09:21:49 ET
- The European Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Inovio ( NASDAQ: INO ) application seeking orphan drug designation for INO-3107 to treat Recurrent Respiratory Papillomatosis (RRP).
- RRP is a rare chronic disease caused by the human papillomavirus (HPV) in which small, wart-like growths occur in the respiratory tract.
- The European Commission will take a final decision on the application within 30 days, the company added.
- The orphan drug status in the EU is aimed at therapies treating or preventing diseases which affect fewer than five in 10,000 people in the EU. The designation provides incentives, including 10 years of market exclusivity for the drug, if approved.
- INO +3.54% to $0.85 premarket April 26
For further details see:
Inovio's respiratory disorder therapy on way to get orphan drug status in EU